Abstract
Purpose To investigate the incidence and clinical significance of platelet responsiveness in patients receiving clopidogrel following peripheral angioplasty procedures. Materials and Methods This prospective study included patients receiving antiplatelet therapy with clopidogrel 75mg after infrainguinal angioplasty or stenting and who presented to our department during routine follow-up. Clopidogrel responsiveness was tested using the VerifyNowP2Y12 Assay. Patients with residual platelet reactivity units (PRU)≥235 were considered as non-responders (resistance to clopidogrel, group R), while patients with PRU Results In total, 113 consecutive patients (mean age 69±8years) with 139 limbs were enrolled. Following clopidogrel responsiveness analysis, 61 patients (53.9%) with 73 limbs (52.5%) were assigned to group R and 52 patients (46.1%) with 66 limbs (47.5%) to group N. Mean follow-up interval was 27.7±22.9 months(range:3-95months). Diabetes, critical limb ischemia and renal disease were associated with clopidogrel resistance (Fisher’s exact test;p Conclusion Resistance to clopidogrel was related with significantly more re-interventions following peripheral angioplasty procedures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
